PD-(L)1双抗,还有5个买家

瞪羚社
Aug 20

上方“瞪羚社”即刻关注并加入社群聚焦高成长公司,15万+投资菁英共同关注在康方生物/的依沃西单抗对外合作交易悬而未决之际,最大竞争对手BMS/Biontech的BNT327可谓是火力全开。2025 WCLC摘要中,Biontech公布了一项BNT327联合化疗治疗一线广泛期小细胞肺癌(ES-SCLC)全球2期临床的初步结果,患者的疾病控制率(DCR)高达100%,并且有将近90%的患者实现早期肿瘤...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10